search
Back to results

Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project (WRAP)

Primary Purpose

Cocaine Use Disorder

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Prize-Based Contingency Management
Treatment As Usual Outpatient Substance Use Treatment
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cocaine Use Disorder focused on measuring Cocaine-Related Disorders, Contingency Management, Reward, Choice Behavior, Executive Function, Precision Medicine, Evidence-Based Practice, Prospective Thinking, Electroencephalography, Event-Related Potentials, Functional Connectivity

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Military Veterans
  • DSM-5 Criteria for Cocaine Use Disorder (Mild, Moderate, or Severe)
  • Cocaine Use Within Past 60 Days
  • Stated Goal of Cocaine Abstinence or Reduced Cocaine Use
  • Normal or Corrected-to-Normal Vision
  • Average or Corrected Hearing

Exclusion Criteria:

  • History of Severe Traumatic Brain Injury, Seizure Disorder, or other Neurological Illness
  • Severe or Unstable Medical or Psychiatric Condition
  • Pregnant or Lactating Women
  • Moderate-to-Severe Neurocognitive Impairment per Medical Record, SLUMS < 21, or Mini MoCA < 11
  • In Ongoing Residential Treatment or Imminently Expected to Enter Residential Treatment During the Study Interval at Time of Screening

Sites / Locations

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PARecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Tangible Prize-Based Contingency Management (TangiblePBCM)

Voucher Prize-Based Contingency Management (VoucherPBCM)

Arm Description

For participants assigned to TangiblePBCM, prize draws resulting in one or more small, large, or jumbo wins will result in access to a prize cabinet stocked with small, medium, large, and jumbo financial incentive items. Medium incentive items are included for selection in the event that a patient draws several small prize slips on the same day and are considered equivalent to 4 small prizes. Selection of specific prize items will be informed by patient preference and items will be restocked at least every 2 weeks. The prize cabinet will be open during TangiblePBCM sessions such that prize items are readily visible. Selection of prizes, maintenance of the prize cabinet, and policies regarding prize redemption will follow published guidance on administration of TangiblePBCM within the context of research protocols.

For participants assigned to VoucherPBCM, prize draws resulting in one or more small, large, or jumbo wins will be reinforced with VA Canteen vouchers in the specified incentive range (i.e., small, large, or jumbo).

Outcomes

Primary Outcome Measures

% Cocaine-Negative Urine Specimens
Proportion of urine specimens provided during the 12-week treatment interval that test negative for cocaine.
Longest Duration of Cocaine Abstinence
Longest period of objectively verified abstinence from cocaine during treatment.

Secondary Outcome Measures

% Contingency Management (CM) Sessions Attended (CM Groups Only)
Proportion of CM treatment sessions attended.
Total Non-CM Treatment Encounters
Number of non-CM treatment encounters during treatment (documented in chart and/or self-reported)
% Self-Reported Cocaine-Abstinent Days During Treatment
Proportion of self-reported cocaine-abstinent days during the 12-week treatment interval.
% Self-Reported Drug- and Alcohol-Abstinent Days During Treatment
Proportion of self-reported drug- and alcohol-abstinent days during the 12-week treatment interval.
% Self-Reported Stimulant-Abstinent Days at Post-Treatment (CM Groups Only)
Proportion of self-reported stimulant-abstinent days during the 6 month post-treatment interval.
% Self-Reported Drug- and Alcohol-Abstinent Days at Post-Treatment (CM Groups Only)
Proportion of self-reported drug- and alcohol-abstinent days during the 6 month post-treatment interval.

Full Information

First Posted
January 7, 2019
Last Updated
March 2, 2023
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT03799341
Brief Title
Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project
Acronym
WRAP
Official Title
Electrophysiological Predictors and Indicators of Contingency Management Treatment Response
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 13, 2019 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The proposed work will investigate changes in brain signaling and cognitive functioning that support recovery from addiction, as well as use of pretreatment neurocognitive functioning to inform substance use treatment planning. Substance use disorders are prevalent amongst Veterans. Cocaine addiction, in particular, has been shown to complicate treatment of other high priority behavioral health problems in the Veteran population (e.g., PTSD, opioid addiction). While there are currently no approved medications to support recovery from cocaine addiction, research indicates that Contingency Management (CM) - a behavioral intervention for cocaine users - can be effective. However, individual responses are variable and long-term benefits are limited. This CDA will test a new model of how CM works by examining brain-based predictors and indicators of treatment response. Results will have immediate implications for measurement-based implementation of existing CM variants within the VA, supporting access to the version of CM that is best aligned with each Veteran's needs.
Detailed Description
Electrophysiological methods, including event-related potential and functional connectivity approaches, have potential to clarify mechanisms of substance use treatment response and characterize individual differences therein. Veterans are disproportionately affected by disorders of addiction, of which cocaine use disorder (CUD) is particularly problematic due to high relapse rates and the absence of approved pharmacotherapy options. Behavioral interventions for CUD have therefore become an important focus and Contingency Management (CM) has emerged as the best-supported approach. CM involves reinforcing cocaine abstinence (established through objective testing) with reliable, short-term reward, such as chances to win prizes (i.e., Prize-Based CM or PBCM). Given robust empirical support, nationwide dissemination of PBCM has been supported by a VHA initiative since 2011. However, PBCM response rates are variable and long-term benefits are limited - problems magnified by the cost of implementation with respect to staffing and prizes. Measurement-based approaches to PBCM implementation have promise to improve the effectiveness and efficiency of CM programming but have not yet been investigated within the VA or considered in relation to promising neuromarkers. Importantly, two versions of PBCM are already utilized at VA sites and may differentially benefit individuals with distinct neurocognitive profiles. Specifically, VA PBCM programs employ either abstract (voucher prize) or concrete (tangible prize) incentives, the latter of which may more effectively incentivize abstinence in Veterans with poor future-oriented thinking and planning ability. While selection between existing PBCM variants currently reflects practical considerations only, pretreatment neurocognitive functioning could meaningfully and realistically inform clinical decision-making in this regard. This project aims to advance measurement-based implementation of CM by testing a novel neurocognitive model with immediate implications for the use of abstract versus concrete PBCM incentives within the VA. Specifically, the future-minded decision-making (FMDM) model posits that CM scaffolds future-oriented goal representation and self-control to support abstinence during in the moment use-related decision-making. For individuals with greater FMDM impairment, concrete, readily-accessible incentives may be more effective than abstract voucher-based rewards (which require future-oriented thinking and planning to acquire value). To test this model, neurocognitive substrates of FMDM will be examined as predictors of differential treatment response in voucher (VoucherPBCM) versus tangible prize (TangiblePBCM) versions of PBCM. Treatment-related change in neural and cognitive-behavioral correlates of FMDM will also be evaluated in PBCM-adherent versus non-adherent subgroups. Veterans with CUD will be allocated to VoucherPBCM or TangiblePBCM conditions and followed for a 12-week treatment interval. Pre- and post-treatment electroencephalography (EEG) and cognitive-behavioral assessments will be used to measure FMDM-related constructs (working memory, self-control, future-oriented decision-making, future reward representation) and related neuromarkers. These measures will be investigated as predictors of differential treatment response in VoucherPBCM versus TangiblePBCM, as well as maintenance of gains during a post-treatment follow-up period. Change in FMDM-related neural and cognitive measures over the course of treatment will also be evaluated for evidence of neuroadaptation (e.g., changes in functional connectivity) and enhancement of FMDM function through PBCM. Taken together, results of the current research project will represent a first step toward precision implementation of CM within the VA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine Use Disorder
Keywords
Cocaine-Related Disorders, Contingency Management, Reward, Choice Behavior, Executive Function, Precision Medicine, Evidence-Based Practice, Prospective Thinking, Electroencephalography, Event-Related Potentials, Functional Connectivity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomly assigned to receive: (1) 12 weeks of TangiblePBCM (n = 70) or (2) 12 weeks of VoucherPBCM (n = 70). CM recipients will also be followed for 6 months post treatment. The proposed design enables evaluation of CM outcome predictors within 140 CM recipients - both with respect to initial treatment response and longer term (6 month) outcomes. All participants will receive a Baseline Assessment prior to the 12 Week Treatment interval, as well as a Follow-up Assessment at the conclusion of this period. Data from Baseline and Follow-up Assessments will enable longitudinal analysis of treatment-related change in EEG and cognitive-behavioral measures in TangiblePBCM and VoucherPBCM in treatment adherent versus treatment non-adherent subgroups.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tangible Prize-Based Contingency Management (TangiblePBCM)
Arm Type
Experimental
Arm Description
For participants assigned to TangiblePBCM, prize draws resulting in one or more small, large, or jumbo wins will result in access to a prize cabinet stocked with small, medium, large, and jumbo financial incentive items. Medium incentive items are included for selection in the event that a patient draws several small prize slips on the same day and are considered equivalent to 4 small prizes. Selection of specific prize items will be informed by patient preference and items will be restocked at least every 2 weeks. The prize cabinet will be open during TangiblePBCM sessions such that prize items are readily visible. Selection of prizes, maintenance of the prize cabinet, and policies regarding prize redemption will follow published guidance on administration of TangiblePBCM within the context of research protocols.
Arm Title
Voucher Prize-Based Contingency Management (VoucherPBCM)
Arm Type
Experimental
Arm Description
For participants assigned to VoucherPBCM, prize draws resulting in one or more small, large, or jumbo wins will be reinforced with VA Canteen vouchers in the specified incentive range (i.e., small, large, or jumbo).
Intervention Type
Behavioral
Intervention Name(s)
Prize-Based Contingency Management
Intervention Description
Participants assigned to Prize-based Contingency Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8 prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment.
Intervention Type
Behavioral
Intervention Name(s)
Treatment As Usual Outpatient Substance Use Treatment
Intervention Description
All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
Primary Outcome Measure Information:
Title
% Cocaine-Negative Urine Specimens
Description
Proportion of urine specimens provided during the 12-week treatment interval that test negative for cocaine.
Time Frame
12-Week Treatment Interval
Title
Longest Duration of Cocaine Abstinence
Description
Longest period of objectively verified abstinence from cocaine during treatment.
Time Frame
12-Week Treatment Interval
Secondary Outcome Measure Information:
Title
% Contingency Management (CM) Sessions Attended (CM Groups Only)
Description
Proportion of CM treatment sessions attended.
Time Frame
12-Week Treatment Interval
Title
Total Non-CM Treatment Encounters
Description
Number of non-CM treatment encounters during treatment (documented in chart and/or self-reported)
Time Frame
12-Week Treatment Interval
Title
% Self-Reported Cocaine-Abstinent Days During Treatment
Description
Proportion of self-reported cocaine-abstinent days during the 12-week treatment interval.
Time Frame
12-Week Treatment Interval
Title
% Self-Reported Drug- and Alcohol-Abstinent Days During Treatment
Description
Proportion of self-reported drug- and alcohol-abstinent days during the 12-week treatment interval.
Time Frame
12-Week Treatment Interval
Title
% Self-Reported Stimulant-Abstinent Days at Post-Treatment (CM Groups Only)
Description
Proportion of self-reported stimulant-abstinent days during the 6 month post-treatment interval.
Time Frame
6 Month Post-Treatment Interval
Title
% Self-Reported Drug- and Alcohol-Abstinent Days at Post-Treatment (CM Groups Only)
Description
Proportion of self-reported drug- and alcohol-abstinent days during the 6 month post-treatment interval.
Time Frame
6 Month Post-Treatment Interval
Other Pre-specified Outcome Measures:
Title
Pre- to Post-Treatment Change in Theta Synchronization
Description
Treatment-related change in theta synchronization between anterior cingulate cortex and lateral prefrontal cortex during high conflict events in the Parametric Conflict Flankers task.
Time Frame
12-Week Treatment Interval
Title
Pre- to Post-Treatment Change in Executive Working Memory
Description
Treatment-related change in Brown-Peterson working memory scores. We will specifically use a modified Brown-Peterson test (Auditory Consonant Trigrams) for which both age- and Veteran-specific norms exist. Summary scores for this measure (including 9-, 18-, and 36-second delay conditions) can range from 0-45, with higher scores indicating improved executive working memory performance.
Time Frame
12-Week Treatment Interval
Title
Pre- to Post-Treatment Change in Episodic Future Thinking Effect (Delay Discounting)
Description
Treatment-related change in the difference in delay discounting slopes (ln(k)) estimated for discounting conditions with and without personally meaningful event tags.
Time Frame
12-Week Treatment Interval
Title
Pre- to Post-Treatment Change Spontaneous Eyeblink Rate
Description
Treatment-related change in spontaneous eyeblink rate at rest.
Time Frame
12-Week Treatment Interval

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Military Veterans DSM-5 Criteria for Cocaine Use Disorder (Mild, Moderate, or Severe) Cocaine Use Within Past 60 Days Stated Goal of Cocaine Abstinence or Reduced Cocaine Use Normal or Corrected-to-Normal Vision Average or Corrected Hearing Exclusion Criteria: History of Severe Traumatic Brain Injury, Seizure Disorder, or other Neurological Illness Severe or Unstable Medical or Psychiatric Condition Pregnant or Lactating Women Moderate-to-Severe Neurocognitive Impairment per Medical Record, SLUMS < 21, or Mini MoCA < 11 In Ongoing Residential Treatment or Imminently Expected to Enter Residential Treatment During the Study Interval at Time of Screening
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah E Forster, PhD
Phone
(412) 360-2365
Email
Sarah.Forster2@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Stuart R Steinhauer, PhD
Phone
(412) 360-2397
Email
Stuart.Steinhauer@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sarah E. Forster, PhD
Organizational Affiliation
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15240
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah E Forster, PhD
Phone
412-360-2365
Email
Sarah.Forster2@va.gov
First Name & Middle Initial & Last Name & Degree
Stuart R Steinhauer, PhD
Phone
(412) 360-2397
Email
Stuart.Steinhauer@va.gov
First Name & Middle Initial & Last Name & Degree
Sarah E. Forster, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
If possible, a de-identified, anonymized dataset will be created and shared. However, specific arrangements for sharing have not yet been made and options for data sharing (for example, the availability of data repositories for electroencephalographic data files), as well as VA policies regarding data sharing may change over the course of the study. A detailed plan for data sharing will be developed and approved upon completion of data collection.

Learn more about this trial

Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project

We'll reach out to this number within 24 hrs